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Basal exposure Therapy: a new 
approach for Treatment-resistant 
Patients with severe and 
composite Mental Disorders
Didrik Heggdal*, Roar Fosse and Jan Hammer
Division of Mental Health and Addiction, Vestre Viken Hospital Trust, Lier, Norway
New treatment approaches are needed for patients with severe and composite mental 
disorders who are resistant to conventional treatments. Such treatment-resistant 
patients often have diagnoses of psychotic or bipolar disorders or severe personality 
disorders and comorbid conditions. In this study, we evaluate basal exposure therapy 
(BET), a novel ward-integrated psychotherapeutic approach for these patients. Central 
to BET is the conceptualization of undifferentiated existential fear as basic to the 
patients’ problem, exposure to this fear, and the therapeutic platform complementary 
external regulation, which integrates and governs the totality of interventions throughout 
the treatment process. BET is administered at a locked-door ward with 6 patient beds 
and 13.5 full-time employees, including a psychiatrist and 2 psychologists. Thirty-eight 
patients who had completed BET were included, all but two being female, mean age 
29.9  years. Fourteen patients had a diagnosis of schizophrenia or schizoaffective 
disorder (F20/25), eight had bipolar disorder or recurrent depressive disorder (F31/33), 
eight had diagnoses in the F40–48 domain (neurotic, stress-related, and somatoform 
disorders), five were diagnosed with emotionally unstable personality disorder (F60.3), 
and three patients had other diagnoses. Twenty of the patients (53%) had more than 
one ICD-10 diagnosis. Average treatment time in BET was 13 months, ranging from 
2 to 72  months. Time-series data show significant improvements in symptoms and 
functioning from enrollment to discharge, with effect sizes at 0.76 for the Dissociation 
Experience Scale, 0.93 for the Brief Symptom Inventory, 1.47 for the Avoidance and 
Action Questionnaire, and 1.42 and 1.56, respectively, for the functioning and symptom 
subscales of the Global Assessment of Functioning Scale. In addition, the patients used 
significantly less antiepileptic, antipsychotic, anxiolytic, and antidepressant medications 
at discharge than at treatment enrollment. Patient improvement across treatment was 
associated with the following duration of time in BET, the successful completions of the 
exposure component of BET, positive changes in experiential avoidance as measured 
with the Acceptance and Action Questionnaire, and high symptom levels and low levels 
of functioning at treatment start. The findings indicate that BET may be a promising 
inpatient psychotherapeutic approach for previously treatment-resistant patients with 
severe and comorbid conditions.
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inTrODUcTiOn
Patients who do not respond to repeated treatments represent a 
particularly demanding challenge for specialized mental health-
care services. These patients have a perpetual need for continued 
care and protection, and the toll on patients and their families in 
terms of suffering and distress is staggering (1–3). For society, 
the cost related to loss of life from suicide, increased drug and 
alcohol abuse, loss of productivity, and increase in overall health 
costs is almost unfathomable (4–6). This article focuses on a diag-
nostically many-faceted subgroup of treatment-resistant patients, 
presenting with schizophrenia spectrum disorders, dissociative 
disorder, bipolar disorder, or complex post-traumatic stress dis-
order (PTSD), often with a diagnosis of one or more comorbid 
personality disorders. The typical clinical picture comprises 
delusions, hallucinations, dissociation, and mood fluctuations, 
more often than not in combination with deliberate self-harm 
and suicide attempts.
Causes for treatment resistance are still unclear, although poor 
insight into the need of treatment may play a role (7, 8). Treatment-
resistant patients in all the noted diagnostic domains often have 
particularly high symptom loads, comorbid conditions, more 
impaired psychosocial functioning including unemployment and 
dependent living conditions, more severe negative symptoms and 
cognitive deficits, more self-injurious behavior, lower quality of 
life, and more often substance abuse and aggressive behavior than 
other patients (2, 9–12).
The patients’ continued suffering and the extensive cost follow-
ing functional impairment make it imperative to develop novel 
and effective treatment approaches. One such possible approach 
is basal exposure therapy (BET), which during the last decade 
has been developed and implemented within the framework of 
ordinary clinical care at a closed inpatient ward at Vestre Viken 
Hospital Trust in Norway (13). In contrast to symptom-oriented 
treatments, the BET modality has a main focus on mobilizing the 
patient’s resources and promotion of autonomy. Throughout its 
developmental phase, BET has been continually evaluated with a 
naturalistic observational study design. This article presents the 
first quantitative study on the effects of BET. Before we describe the 
BET modality, we summarize existing evidence from controlled 
studies, primarily randomized controlled trials, on treatment 
options for this treatment-resistant patient group.
controlled evidence of effective 
approaches
Patients with schizophrenia who do not respond to recommended 
doses of antipsychotic medication have received considerable 
interest in the scientific literature. Only sporadic attention has 
been paid to treatment-resistant patients with other diagnosis, 
including bipolar disorder, severe and composite personality 
disorders, and dissociative disorders.
In general, the majority of treatment attempts for the patient 
group have been psychopharmacological, often poly-pharmacy 
that has not been covered by pharmacological guidelines (14) 
or other biological interventions, e.g., electroconvulsive therapy, 
transcranial magnetic stimulation, transcranial direct current 
stimulation, and deep brain stimulation (11). A review of 280 
available RCT studies for treatment-resistant schizophrenia 
 concluded that there is a paucity of trials for most types of 
therapeutic approaches. The exception is clozapine, but with 
only modest effects indicated (15). A small set of studies evalu-
ated cognitive behavioral therapy (CBT) for non-responding 
schizophrenic patients, but without finding positive effect (16). 
We identified only one controlled study that reported positive 
effects for a psychotherapeutic approach. In this study, patients 
with “chronic schizophrenia” who were on maintenance medica-
tion exhibited a small improvement in community functioning 
and symptoms of auditory hallucinations after receiving cognitive 
adaptation training compared to CBT and treatment as usual (17).
A review of the best-quality RCT studies for treatment-resist-
ant bipolar disorder/bipolar depression identified only seven 
trials, five medical treatments and two electroconvulsive therapy 
treatments (18). In concluding the review, Sienaert et  al. (18) 
characterized the current status of treatments for these patients 
as “experimental only.” A small set of other approaches have been 
described, including behavioral therapy, sleep deprivation, light 
therapy, and CBT but with effects that appear to be limited (19). 
We found no RCT studies for treatment-resistant dissociative 
disorders or (composite) personality disorders.
Suggestive evidence has been presented in a small set of studies 
based on non-randomized trials and case studies. Chakhssi et al. 
(20) reported small-to-moderate decreases in general psychopa-
thology and pathological personality traits by both acceptance 
and commitment therapy and CBT for patients with personality 
disorders who had not responded to outpatient treatment. In a 
case-control study, Bales et al. (21, 22) found improvement after 
mentalization-based therapy on several measures in a cohort 
study of treatment-resistant patients with borderline personality 
disorder and comorbid conditions, the latter including other 
personality disorders, anxiety disorders, mood disorders, eating 
disorders, and substance abuse disorder. Chlebowski and Gregory 
(23), using dynamic deconstructive psychotherapy, reported 
nominal reductions in dissociative scores in three patients with 
combined dissociative identity disorder and borderline person-
ality disorder, a comorbid condition where no evidence-based 
treatment exists.
Basal exposure Therapy
Basal exposure therapy was developed out of a need for novel 
treatments for low-functioning patients with severe and comorbid 
conditions who had not benefited from multiple prior treatment 
attempts. The BET approach originated with hypothesizing two 
main pathological mechanisms that cross diagnostic categories 
and may generate symptoms and undermine patients’ capability 
to regulate emotion and behavior. First, at a phenomenological 
level, recurrent observations seem to indicate that these patients 
suffer an impending existential anxiety. This anxiety appears 
to be associated with and trigged by affective arousal, which 
instigates experiential avoidance (EA) (24, 25). The habit to 
avoid may maintain and reinforce the patient’s problems (26, 
27). Over time, the fear of affective arousal may evolve into 
a persistent phobic condition, which in BET is labeled basal 
phobia or existential catastrophe anxiety. Basal phobia contrasts 
qualitatively with distinct affect phobias, e.g., fear of guilt, anger, 
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and sadness (28). Explorations indicate that this basal phobia 
typically is experienced as fear of disintegrating or falling apart, 
being engulfed by total emptiness or stuck in eternal pain (29). 
The desperation to use whatever means available to terminate 
affective arousal and avoid the impending catastrophe often 
seems to leave these patients with suicide as the ultimate choice. 
Second, at an interpersonal level, the patients’ treatment histories 
are typically characterized by the health-care system’s repetitive 
efforts to regulate symptoms and behavior by imposing high 
levels of restriction, excessive use of psychopharmacological 
interventions and coercive measures such as forced medication, 
and physical and mechanical restraints. The individual response 
to excessive external regulation may depend on the patient’s 
typical attachment strategies (30, 31). Some patients in the BET 
program report that health-care workers’ efforts to impose con-
trol increased opposition and hostility, while others reacted with 
despair and helplessness (32).
With reference to these pathological mechanisms and with 
an ambition to reinstate the patients’ own capability to regulate 
emotion and behavior, two main components of the BET model 
were developed. These are, first, BET as a psychotherapeutic 
approach and distinct exposure procedure and, second, the 
autonomy- promoting strategy complementary external regula-
tion (CER) (32). CER is a contextual calibration tool with the 
intended function to prevent and reverse pathology-maintaining 
interactions between the patient and health professionals. This 
strategy represents the coordinating platform from which the 
total body of psychotherapeutic and milieu therapeutic inter-
ventions are organized and administrated 24/7 throughout the 
treatment process.
Basal exposure therapy can be seen as a second-order change 
intervention aiming at helping the patients to relate to pain and 
fearful inner experiences instead of using problem-maintaining 
avoidance strategies (33). In BET, learning to relate to pain as 
a part of life is more or less caricatured and taken to extremes. 
However, radical acceptance of the most aversive and frighten-
ing inner experiences, i.e., the existential catastrophe anxiety, is 
hypothesized within the BET approach to augment these patients’ 
treatment response considerably. Within this ambition, BET 
aims at a process-oriented use of medication, where medica-
tion is reduced concomitant with patient improvement. Hence, 
CER-supported psychotherapy is the primary intervention, while 
medication is secondary.
aims
We used a naturalistic within-subject time-series design to evalu-
ate changes in symptoms and functioning for the first 38 patients 
who have completed BET and provided evaluation data. We also 
aimed at testing the involvement of central-specific therapeutic 
features in BET and the role of psychopharmacological treat-
ment. Our research hypotheses were as follows: (1) at discharge 
compared to enrollment to BET, patients exhibited lower levels of 
symptoms and higher levels of functioning; (2) the patients’ use of 
psychopharmaca is reduced across treatment, with no “compen-
satory” increase in the use of alcohol or drugs; (3) reduced EA 
across the treatment course is associated with improvements in 
symptoms and functioning; (4) improvements in symptoms and 
functioning are associated with the degree to which the exposure 
component of BET was successfully completed; and (5) those 
patients with the lowest level of symptoms and the highest level of 
functioning at discharge tend to be those who exhibit the lowest 
levels of dissociation and EA. In addition, we examined (6) the 
influence of time spent in BET on improvement in symptoms and 
functioning.
MaTerials anD MeThODs
Basal exposure therapy is implemented at an inpatient ward for 
psychotic and complex disorders at Vestre Viken Hospital Trust 
in Eastern Norway. The hospital trust provides specialized mental 
health services for a community population of approximately 
470,000. Patients are admitted to the ward from other clinical 
units covered by the hospital trust as well as from other hospital 
trusts. Since BET represents a contrasting alternative to inpatient 
approaches that to a larger extent focus on symptom reduction, 
a  priority at the outset has been to establish a naturalistic and 
systematic evaluation frame. This framework allows for within-
subject time-series analysis of changes in patient symptoms and 
functioning across the treatment course.
Participants
The inclusion criteria to BET are (1) persistently low, falling 
or dramatically fluctuating levels of psychosocial functioning 
characterized by Global Assessment of Functioning (GAF) Scale 
scores below 35; (2) diagnosis of schizophrenia spectrum disor-
ders, bipolar disorder, PTSD, dissociative disorder, or composite 
personality disorder; and (3) prior outpatient and inpatient treat-
ment histories, with adequate treatments but no lasting improve-
ment. The treatment histories often have been characterized by 
excessive symptoms that were either manifest or fluctuating and 
combined with high levels of turmoil and/or deep resignation. 
Patients are excluded when the personality is dominated by per-
sistent hostility, when they are developmentally challenged (IQ 
below 70), and when they have a history of extensive substance 
abuse combined with violent behavior and pronounced cognitive 
impairment. Patients with a brain organic disorder are excluded, 
with the exception being such patients who for years are not han-
dled by other parts of the treatment system and remain extensive 
users of inpatient services. Moreover, patients are excluded when 
they present exclusively with an unequivocal personality disorder 
diagnosis, typically the emotionally unstable type, following 
guidelines that these patients should not receive long-term treat-
ment at inpatient wards (34). The exception is when such patients 
have particularly long and turbulent treatment histories with 
repetitive and dramatic suicide attempts, resulting in prolonged 
hospital stays and the excessive use of force.
By using these criteria, to date, 49 patients have been enrolled 
to BET. Six of these patients are currently in treatment. Two for-
mer patients decided to end BET before treatment completion, 
one died by overdose of illegal drugs, and two were transferred 
to other types of hospital treatments when it became clear that 
the exclusion criterion of persistent hostility was encountered. 
The participant group available for this publication consists of 38 
patients, mean age 29.9 years (SD = 8.1). All but two patients were 
TaBle 1 | Diagnoses at admission to basal exposure therapy.
icD-code Main diagnosis n n with comorbid  
disorder
comorbid disorders in subgroup
F20/25 Schizophrenia 8 5 Alcohol dependence, other psychoactive substance dependence, post-traumatic stress 
disorder (PTSD), emotionally unstable personality disorderSchizoaffective disorder 6
F31/33 Bipolar affective disorder 4 7 Alcohol dependence, poly-substance drug use, social phobias, obsessive-compulsive 
disorder, PTSD, anorexia nervosa, bulimia nervosa, paranoid personality disorder, 
emotionally unstable personality disorder, personality disorder unspecified, dependent 
personality disorder, enduring personality change after catastrophic experience, 
disturbance of activity and attention
Recurrent depressive disorder 4
F40–49 Obsessive–compulsive 
disorder
4 6 Major depressive episode, recurrent depressive disorder, phobic anxiety disorders, 
PTSD, anorexia nervosa, emotionally unstable personality disorder, avoidant personality 
disorder, personality disorder unspecified, mixed and other personality disordersPTSD or dissociative disorder 4
F60.3 Emotionally unstable 
personality disorder
5 2 Alcohol abuse, major depressive episode, persistent mood (affective) disorders, phobic 
anxiety disorders, anorexia nervosa, bulimia nervosa
Other 3a
aOne of these patients was diagnosed with psychotic disorder.
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female. This gender bias may reflect the organization of the ser-
vices in the hospital trust. While low-functioning female patients 
who present with chronic suicidality typically are referred to BET, 
their male counterparts with higher levels of hostility and antiso-
cial characteristics usually are transferred to high-level security 
wards or other psychosis wards.
The patients were diagnosed by use of the ICD-10 diagnostic 
system (35). For the study, we used the diagnoses set by the refer-
ring institutions, which are presented in Table 1.
Average treatment time in the BET program for the 38 patients 
was 13 months, ranging from 2 to 72 months. All patients pre-
viously had both outpatient and inpatient treatments, with a 
mean of 8.0 years (SD = 5.9 years) since the first admittance to 
inpatient treatment in specialized mental health care. All patients 
had multiple (at least two) previous treatment attempts with 
psychopharmaca adequate to main diagnosis.
The BeT Program
Basal exposure therapy is administered at a locked-door ward 
with 6 patient beds and 13.5 full-time employees, including a 
psychiatrist and two psychologists. The program is treatment 
intensive and strictly organized. In the study period, duration 
of treatment time in BET was individually customized to each 
patient’s needs. Each patient has a treatment team with a team 
coordinator, a psychologist or psychiatrist, and two or three 
trained co-therapists (nurses or other milieu therapists). There 
is one daily individual therapy session with one of the therapists, 
who take turns to vary the contextual components and prevent 
the process from becoming static. In addition, there are 5-min 
focus sessions every morning and evening. These sessions are 
used, respectively, to identify and formulate a specific challenge 
for the day and to identify and reflect on what the patient has 
learned. The purpose of framing the therapeutic workday with 
focus sessions is to increase the learning effect and promote 
commitment to treatment. The patients participate in their 
own treatment and team meetings and in a weekly psycho-
educative group (not group therapy), which once a month is led 
by a former BET patient. In most cases, there are two to three 
sessions with close relatives in the treatment process to eliminate 
or modify the effects of pathology maintaining factors in the 
patient’s social relationships. Likewise, routine meetings with 
the general practitioner, outpatient therapist, and community 
health services ensure that follow-up treatment supports patient 
autonomy.
When a patient is admitted to the BET program, the first task 
of the treatment team is to facilitate cooperation and compliance 
with the program’s treatment goals. Initially, the main strategy 
is systematic psychoeducation combined with the therapeutic 
stance inherent in CER. By putting into practice the existential 
postulate that all human beings are free and create their own lives 
by deliberate choices and actions (36), CER seeks to reallocate 
responsibility and locus of control. CER alternates between 
two sets of opposite contextual approaches. The primary CER 
regime is under-regulation, which is characterized by a general 
normalization of all interaction. Examples here are that the 
patients on the one hand are free to do what they want, e.g., go 
for a walk whenever they feel like going for a walk, and on the 
other hand, that they are expected to be accountable when it 
comes to keeping appointments they make and to inform the 
staff if they change their plans. In the under-regulation regime, 
validation and solution-focused interventions are used to 
optimize and consolidate autonomous functioning (37, 38). The 
back-up regime, over-regulation, is a motivating standstill with 
strict focus on safety. Over-regulation is used only if the patients 
repeatedly fail to obtain self-regulation and life and health are at 
risk. However, this regime is not characterized by the use of force 
but by validating care and a focus on the patient’s situational 
options and actions. The treatment team is awaiting the patient’s 
initiative to a “coping-dialog.” When he or she have described 
coping strategies that may be functional alternatives to acting 
out or self-destructive behavior and have expressed motivation 
and willingness to try out these strategies, the regime is switched 
back to under-regulation. CER may metaphorically be denoted 
as a “secure base,” borrowing Bowlby’s (39) term for the rela-
tional platform that children need in order to follow the normal 
path of development. To enable therapists and staff to adjust the 
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administration of CER to the individual patient’s attachment 
strategies, BET has included basic elements from the dynamic-
maturational model (DMM) (30, 40). In DMM-informed CER, 
potential pitfalls associated with regression are predicted and 
detected and then averted by various strict forms of validat-
ing interventions. The treatment team continuously monitors 
patients’ regressive and progressive responses. If indicated, the 
two regimes are switched back and forth to facilitate progressive 
responses.
When a sufficiently stable working alliance is established, the 
next objective, and the core intervention in BET, is to replace 
excessive avoidance of existential catastrophe anxiety with 
exposure and acceptance. First, patient and therapist explore 
and identify the patients’ typical avoidance behaviors, including 
physical behaviors, body posture, restricted respiration, the way 
he or she talks, and mental maneuvers like intellectualization and 
externalization. Then the patient is invited to expose himself or 
herself by choosing not to avoid, i.e., refrain from doing what 
he or she usually does to keep affective arousal at a bearable 
level. By this therapeutic procedure, the patient realizes step by 
step, and also by flooding experiences (41), that what used to be 
experienced as existential threats may be unpleasant and painful, 
but no longer dangerous. When the patient begins to choose 
exposure as opposed to avoidance, solution-focused interven-
tions (38) are used to reinforce and consolidate self-exposure 
and self-regulating skills and consequently self-efficacy and 
empowerment.
Measures and Procedures
We used the split version of the GAF scale to assess general func-
tioning and symptoms. GAF constitutes Axis V in DSM-IV-TR 
(42) and aims at global psychological, social, and occupational 
characteristics. The reliability of GAF is considered improved 
when several raters are used (43). We determined GAF as con-
sensus scores between two or three trained clinicians based on 
clinical observations on the ward from the last week. All raters 
were trained according to national procedures (44).
Patients scored their own symptoms with the Brief Symptom 
Inventory (BSI), which consists of 53 items scored on 5-point 
Likert scales. The BSI includes nine subscales: somatization, 
compulsiveness, interpersonal sensitivity, depression, anxiety, 
hostility, paranoid thoughts, and psychoticism. In the analysis, 
we used the Global Severity Index (GSI), defined as the mean 
score across the 53 items. BSI (and GSI) has good psychometric 
properties, with Cronbach’s alpha between 0.71 and 0.85 (45).
Dissociation was measured with the Dissociation Experiences 
Scale (DES) (46). DES is a self-rating form that measures the 
degree of experienced dissociation and consists of 28 items. Each 
item is scored with respect to the proportion of time that the 
dissociative symptom is experienced, ranging from 0% (never) 
to 100% (always). DES has test-retest reliability at 0.84–0.96 and 
Cronbach’s alpha at 0.95 (46, 47).
Experiential avoidance was assessed using the Acceptance 
and Action Questionnaire (AAQ). AAQ is a self-rating form 
originally designed to measure EA in terms of psychological flex-
ibility vs. inflexibility (24). Low EA is associated with the use of 
second-order coping strategies, which is a central concept and the 
primary treatment goal in BET (33). We used the original nine-
item version of the AAQ, which has adequate criterion-related, 
predictive, and convergent validities1. We had the AAQ translated 
to Norwegian following standard procedures.
Patients rated their own use of alcohol and drugs with the 
Alcohol Use Disorder Identification Test (AUDIT) (48) and Drug 
Use Disorders Identification Test (DUDIT) (49). The AUDIT 
includes 10 questions about hazardous and harmful patterns of 
alcohol use and dependence. The DUDIT includes 11 questions 
about harmful use or abuse of a list of drugs. Both instruments 
have satisfactory psychometric properties in clinical and non-
clinical samples, with overall reliability above 0.80 and convergent 
validity, sensitivity, and specificity above 85% (50–53).
Information on the use of medications was extracted from 
the patients’ medical charts in the electronic patient journals. 
We focused on regular medications (and doses) at enrollment 
to BET and at discharge for the following five WHO-defined 
categories: N03A antiepileptics, N05A antipsychotics, N05B 
anxiolytics, N05C hypnotics, and N06A antidepressants. We 
transformed the dose of each medication that the patients had 
been administered into defined daily doses (DDD), according to 
WHO guidelines (http://www.whocc.no/atc_ddd_index/), and 
summed together DDDs for different drugs that belonged to the 
same category.
Exposure to distressing and aversive thoughts and feelings is 
a core therapeutic component of BET. However, the degree to 
which patients have completed exposure has varied, reflecting 
the degree to which a productive working alliance has been 
established, i.e., whether the patient hesitates or actively commits 
herself/himself and engages in exposure therapy. We quantified 
the exposure component of BET on a 0 to 3 scale, with 0 rep-
resenting no exposure, 1 some degree of/intermittent exposure, 
2 systematic work with graded exposure, and 3 flooding (trials 
of full exposure). Two clinicians, who knew all the patients and 
their therapeutic processes well, independently used the exposure 
scale to score each patient. For 29 of the 38 patients (76%), the 
2 raters gave the same score. For the nine patients with deviant 
scores, the raters subsequently reached a consensus decision. For 
the statistical analysis, we dichotomized the variable and sorted 
patients scored at 0 or 1 into a “low-exposure” group and those 
scored at 2 or 3 into a “high-exposure” group. On this dichoto-
mized variable, the two raters initially agreed on the exposure 
score for 37 of the 38 patients (97%).
statistical analyses
The scores on GAF, GSI, DES, and AAQ were normally dis-
tributed, and changes from enrollment to discharge from BET 
were analyzed with paired sample t-tests. Effect sizes (Cohen’s 
d) were calculated for each measure, using test statistics from 
the dependent t-test (t, r, n), see http://www.psychometrica.de/
effect_size.html. The use of medications was positively skewed 
for all medication categories. The same was the case for scores on 
AUDIT and DUDIT. Changes in these variables from enrollment 
1 Hayes SC, Bissett RT, Strosahl KD, Wilson KD, Pistorello J, Dykstra TA. 
Psychometric Properties of the Acceptance and Action Questionnaire (AAQ) (2000). 
Unpublished manuscript.
FigUre 2 | changes in global severity index from enrollment to 
discharge. Lines are SEs.
FigUre 1 | changes in global assessment of Functioning from 
enrollment to discharge. Lines are SEs.
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to discharge were analyzed with Wilcoxon signed-rank test for 
related samples.
To analyze the possible contribution of changes in EA, meas-
ured with AAQ, on changes in GAF, GSI, and DES from enroll-
ment to discharge, we first calculated changes in AAQ scores 
for each patient. The resulting variable was dichotomized into a 
“low-change” group who changed at or below the median (less 
than or equal to nine points on the AAQ) and a “high-change” 
group who changed above the median. We then used independ-
ent sample t-tests to analyze if AAQ group (low, high) had an 
effect on changes in the outcome measures. Likewise, the con-
tribution of the exposure component of BET on changes in the 
outcome measures was analyzed with independent sample t-tests, 
using exposure level (low vs. high) as dichotomized independent 
variable.
Pearson correlation analysis was used to investigate the asso-
ciation between time spent in BET and changes in the outcome 
measures from enrollment to discharge. For outcome measures 
that were significantly associated with time in BET, we continued 
with regression analysis, using time in BET and degree of expo-
sure (low, high) as predictors, and, as dependent variable, change 
in the outcome measure.
Next, we used Pearson correlation tests to analyze whether, 
at discharge, lower scores on DES and higher scores on AAQ 
were associated with low symptom and high functioning scores 
(GAF and GSI). In a final series of analysis, we tested whether 
patient characteristics at enrollment could predict scores on the 
outcome measures at discharge. Independent sample t-tests were 
used to test whether two diagnostic categories, schizophrenia 
and other psychosis with or without comorbid conditions 
(“psychosis”) (n =  15) vs. non-psychotic, comorbid conditions 
(“non-psychotic”) (n = 23) (see Table 1) were differentially asso-
ciated with changes in the outcome measures. To analyze whether 
scores on the outcome measures at enrollment were associated 
with changes in the same measures from enrollment to discharge, 
we used Pearson r.
Outcome data were available for all patients only for GAF. 
Patients with missing data on a given variable were excluded 
from all analyses where this variable was used. The analyses were 
performed in SPSS version 23.
ethics statement
The Regional Committees for medical and health research ethics 
has considered this evaluation study as a systematic self-evaluation 
of clinical practice outside their mandate. The Data Protection 
Office for Research in Vestre Viken has approved publishing the 
data. The Data Protection Office stated that the topic is of great 
public interest, and informed consent was not deemed necessary 
because it would be impossible to identify the individual patients 
from the aggregated data analyzed in the study.
resUlTs
The patients’ ICD-10 diagnoses at enrollment to BET are summa-
rized in Table 1. The 38 patients spent an average of 13.1 months 
(SD = 14.4) in BET.
changes from enrollment to Discharge
Significant changes (improvements) from enrollment to dis-
charge were seen in both GAF-S, mean 32.7 vs. 47.2, t(37) = 6.5, 
p < 0.001, and GAF-F, mean 32.8 vs. 45.7, t(37) = 6.2, p < 0.001 
(Figure 1). Effect sizes (Cohen’s d) were large: 1.56 for GAF-S and 
1.42 for GAF-F.
Significant improvements (p < 0.001) at discharge compared 
to enrollment to BET were also seen for GSI, mean 3.0 vs. 2.4, 
t(28)  =  4.5, p  <  0.001 (Figure  2), DES, mean 32.7 vs. 19.8, 
t(28) = 4.9, p < 0.001 (Figure 3), and AAQ, mean 52.5 vs. 41.4, 
t(29) = 7.3, p < 0.001 (Figure 4). Effect sizes were d = 0.93 for 
GSI, d = 0.76 for DES, and d = 1.47 for AAQ.
The use of medications at enrollment and discharge from BET 
is illustrated in Figure 5 and depicted in more detail in Table 2. 
Significant reductions across treatment were seen for antiepilep-
tics, p = 0.033, antipsychotics, p = 0.002, anxiolytics, p = 0.028, 
and antidepressants, p < 0.001, with a similar trend for hypnotics, 
p = 0.066.
FigUre 3 | changes in Dissociation experience scale from 
enrollment to discharge. Lines are SEs.
FigUre 4 | changes in experiential avoidance (acceptance and 
action Questionnaire) from enrollment to discharge. Lines are SEs.
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No significant changes from enrollment to discharge were 
seen for AUDIT, mean 5.2 vs. 4.5, p = 0.43, or DUDIT, mean 3.0 
and 3.4, p = 0.73.
analysis of Therapeutic Mechanisms
As shown in Table  3, participants with high improvements 
compared to those with low improvements in EA (AAQ) had 
significantly higher improvements on GAF-S, p  =  0.002 and 
GAF-F, p = 0.005, but not on GSI or DES.
As seen in Table 4, patients with a high degree of completion 
compared to those with a low degree of completion of the expo-
sure component of BET had significantly larger improvements on 
GAF-S, p = 0.025, GAF-F, p = 0.008, and GSI, p = 0.030, with a 
similar trend for DES, p = 0.055.
At discharge, low dissociation (measured with DES) and 
low EA (measured with AAQ) were moderately correlated with 
high scores on GAF-F and GAF-S (less symptoms and better 
functioning) and with low scores on GSI (less symptoms), 
p values ≤ 0.031 (Table 5). The correlations were not due to 
outliers, as illustrated in Figures  6A,B for AAQ vs. GAF-S 
and GSI.
Time in BET was associated with changes in GAF-S, r = 0.44, 
p = 0.006, and GAF-F, r = 0.47, p = 0.003, but not with changes 
in GSI, DES, or AAQ, p values >0.60. When including degree of 
exposure in addition to time in BET as predictor of changes in 
GAF scores, in linear regression analysis, effects were seen for 
both predictors; GAF-S—time in BET, t = 3.5, β = 0.47, p = 0.001, 
degree of exposure, t = 2.9, β = 0.40, p = 0.006; GAF-F—time 
in BET, t = 4.0, β = 0.51, p < 0.001, degree of exposure, t = 3.6, 
β = 0.46, p = 0.001. The Durbin–Watson coefficients were nor-
mal, d = 2.01 for GAF-S and d = 1.88 for GAF-F, indicating no 
autocorrelation between residuals.
Patient Predictors of improvement
In a final series of t-tests and correlation analysis, we tested 
whether patient characteristics at baseline were associated with 
improvement at discharge. t-tests revealed no associations 
between 2 broad diagnostic categories (15 patients with psycho-
sis vs. 23 patients without psychosis) and changes in any of the 
outcome measures, p values > 0.20. In contrast, the patients with 
the lowest scores on the outcome measures at enrollment to BET 
tended to have the largest improvements on the same measure 
at discharge. This was evident for GAF-S, r = −0.78, p < 0.001, 
GAF-F, r = −0.72, p < 0.001, and DES, r = −0.53, p = 0.003, with 
similar trends for GSI, r = −0.35, p = 0.06, and AAQ, r = −0.30, 
p = 0.11.
DiscUssiOn
Patients who previously had not responded to repetitive treat-
ment attempts showed improved symptoms and functioning 
after inpatient treatment with BET. The following pattern of 
improvements was observed across diagnostic categories. At 
discharge compared to enrollment, reduced symptoms were 
evident as higher scores on GAF-S and lower scores on BSI and 
DES, whereas improved functioning was evident as increased 
scores on GAF-F. Lower scores on AAQ at discharge compared to 
enrollment indicated reduced EA. Effect sizes were large, ranging 
from 0.76 for DES to 0.93 for GSI, 1.42 for GAF-F, 1.47 for AAQ, 
and 1.56 for GAF-S. In addition, the patients used less regular 
medications, i.e., antiepileptic, antipsychotic, anxiolytic, and 
antidepressant, at discharge than at treatment enrollment, with 
no concomitant increases in the use of alcohol or drugs. Patient 
improvement across treatment was associated with successful 
completion of the exposure component of BET, reduction in EA, 
high symptom levels and a low level of functioning at treatment 
start, and the duration of time in BET. At discharge, patients with 
the lowest levels of dissociation and EA tended to have the highest 
level of functioning (GAF-F) and the lowest level of symptoms 
(GAF-S and GSI).
TaBle 4 | changes in outcome measures as a function of low and high 
completion of the exposure component of basal exposure therapy.
Outcome 
measure
Mean changes t Value  
(df)
P value
low exposure high exposure
GAF-S +9.9 +19.7 2.3 (36) 0.025
GAF-F +7.8 +18.5 2.8 (36) 0.008
BSI: GSI-score −0.32 −0.90 2.3 (27) 0.030
DES −7.5 −17.3 2.0 (27) 0.055
GAF, Global Assessment of Functioning, symptom (S) and functioning (F) subscales; 
GSI/BSI, Global Severity Index from the Brief Symptom Inventory; DES, Dissociation 
Experience Scale.
TaBle 3 | changes in outcome measures as a function of low and high 
changes on the acceptance and action Questionnaire (aaQ).
Outcome 
measure
Mean changes t Value  
(df)
P value
improvement  
on aaQ: low
improvement  
on aaQ: high
GAF-S +6.5 +21.5 3.6 (28) 0.002
GAF-F +5.7 +16.3 3.1 (28) 0.005
BSI: GSI-score −0.46 −0.79 1.21 (27) 0.24, ns
DES −11.5 −13.5 0.37 (27) 0.72, ns
GAF, Global Assessment of Functioning, symptom (S) and functioning (F) subscales; 
GSI/BSI, Global Severity Index from the Brief Symptom Inventory; DES, Dissociation 
Experience Scale.
FigUre 5 | changes in psychopharmacological treatment from enrollment to discharge. Lines are SEs.
TaBle 2 | Use of regular medications at admission and discharge.
icD-code Medication  
type
admission Discharge
n M DDDa (sD) n M DDDa (sD)
F20/25 
(n = 14)
Antiepileptics 3 0.95 (0.62) 2 0.9 (0.14)
Antipsychotics 12 1.62 (1.34) 9 1.0 (0.38)
Anxiolytics 3 2.17 (1.04) 0 –
Hypnotics 3 1.67 (0.58) 0 –
Antidepressants 6 2.04 (1.25) 2 1 (0)
F31/33 
(n = 8)
Antiepileptics 4 0.83 (0.45) 0 –
Antipsychotics 6 0.55 (0.43) 3 0.44 (0.35)
Anxiolytics 1 0.9 (0) 0 –
Hypnotics 0 – 0 –
Antidepressants 4 1.1 (0.57) 0 –
F42–44 
(n = 8)
Antiepileptics 1 2.67 (0) 0 –
Antipsychotics 4 1.58 (0.68) 2 1.54 (1.0)
Anxiolytics 1 0.3 (0) 0 –
Hypnotics 1 1 (0) 1 0.67 (0)
Antidepressants 6 2.21 (1.42) 3 2.93 (1.68)
F60.3 
(n = 5)
Antiepileptics 2 1.17 (0.71) 1 0.83 (0)
Antipsychotics 4 0.85 (0.43) 3 0.9 (0.74)
Anxiolytics 1 0.92 (0) 0 –
Hypnotics 1 1 (0) 1 1
Antidepressants 3 2.25 (0.9) 0 –
Other  
(n = 3)
Antiepileptics 0 – 0 –
Antipsychotics 0 – 0 –
Anxiolytics 1 0.3 1 0.3
Hypnotics 0 – 0 –
Antidepressants 2 0.88 (0.18) 2 0.75 (0.35)
aMean defined daily doses (DDD) for those who used the medication. Four participants 
had missing data.
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One possible explanation to the improvements we observed 
is that patients were protected against the hassles and stresses 
of daily life while staying at the inpatient ward. In line with this 
possibility, longer time in BET was associated with stronger 
improvements in GAF scores. While protection against life 
stress may have played a role, regression analyses indicated 
that this was not the entire answer. Even if time in BET was the 
best predictor, independent effects on changes in GAF scores 
were seen for the degree to which the patients completed the 
TaBle 5 | associations of dissociation (Des) and ea (aaQ) with gaF and 
gsi at discharge.
gaF-s gaF-F gsi
DES r = −0.40; p = 0.031 r = −0.42; p = 0.025 r = 0.52; p = 0.004
AAQ r = −0.52; p = 0.003 r = −0.49; p = 0.006 r = 0.54; p = 0002
GAF, Global Assessment of Functioning, symptom (S) and functioning (F) subscales; 
GSI/BSI, Global Severity Index from the Brief Symptom Inventory; DES, Dissociation 
Experience Scale.
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exposure component of BET. Three other observations were 
consistent with the notion that BET had contributed to the 
patients’ improvements. First, the degree of completion of the 
exposure component, but not time in BET, also was associated 
with improvements on BSI and DES. Second, patients who 
underwent highest reduction in EA also had more improve-
ments on GAF-S and GAF-F. Third, at discharge, patients with 
lowest EA and the lowest degree of dissociation tended to have 
the best scores on GAF and GSI.
effects of second-Order change 
interventions
Significant reductions of dissociation (DES) and EA (AAQ), and 
these measures’ relationship to the other outcome parameters in 
the study, indicate that habitual avoidance to a large extent had 
been replaced with self-exposure and acceptance. The combina-
tion of findings may support the notion that second-order change 
interventions and improvement of psychological flexibility may 
be a feasible alternative to treatments that directly focus on 
symptom reduction in this patient population (26, 27). While 
we are aware of no comparative evidence for this conclusion 
regarding our patient group, changes in EA have been associated 
with symptom improvement in less ill patients. Hayes et al. (27) 
found that higher levels of EA were associated with a lower qual-
ity of life and higher levels of general psychopathology. In US 
samples, upper quartile scores on the 9-item version of the AAQ 
that we used have been reported at 42 in clinical samples drawn 
from people in outpatient psychotherapy with mild-to-moderate 
problems, and at 38 for non-clinical populations (undergradu-
ate students) (27). Average AAQ scores in our patient group 
decreased significantly from 52.5 at BET enrollment to 41.4 at 
discharge. With the reservation that normative Norwegian data 
are lacking on the AAQ, our AAQ data indicate that while the 
BET patients at enrollment exhibited EA at levels associated with 
extremely high symptom loads and severe psychosocial prob-
lems, they presented with only mild-to-moderate psychological 
difficulties at discharge.
Since the goal of BET is to enable patients to cope with 
aversive and stressful inner experiences, treatment success 
would mean a reduced need for medication. The results show 
significant reductions in four of five medication categories, with 
a similar trend for the fifth category. At discharge, the patients 
had not compensated for reduced medications with increased 
use of alcohol or illegal drugs. This underscores the interpreta-
tion that BET facilitated second-order change processes and that 
there was no contribution from medications to the observed 
improvements.
The reduced EA and increased ability to self-regulate may 
indicate that BET has enhanced empowerment and autonomy. If 
this is correct, the patients through BET have attained ownership 
to tools that may lead to further improvement after discharge. 
Increased emotional and cognitive self-regulation may have 
reduced the patients’ emotional reactivity and increased their 
ability to handle negative emotions, relate to stress, choose 
from alternatives, make plans, and control their own behavior 
FigUre 6 | examples of correlations at discharge: aaQ vs. gaF-s and gsi. AAQ, Acceptance and Action Questionnaire; GSI, Global Severity Index from the 
Brief Symptom Inventory; GAF-S, Global Assessment of Functioning, symptom subscale. Correlations: (a) AAQ vs. GAF-S, r = −0.52. (B) AAQ vs. GSI, r = 0.54.
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in a flexible manner (54). The underlying neuropsychological 
changes may include an increased capability to utilize frontal 
cortical systems to maintain cognitive control in situations with 
activation of subcortical emotion structures such as the amygdala 
(55, 56).
Exposure therapy is widely accepted as the treatment of choice 
for phobic conditions (57), and exposure is assumed to be the 
core psychotherapeutic change mechanism in BET. The results 
reveal that the patients who involved themselves in systematic 
graded exposure and flooding (high degree of exposure) ben-
efited significantly more from treatment than those who did 
not (low degree of exposure). This may indicate that the specific 
component of basal exposure significantly contributed to the 
observed positive treatment responses. As a psychotherapeutic 
intervention, basal exposure is administrated as an inhibitory 
learning procedure (58). In contrast to habituation models of 
exposure (41), the ambition is not fear reduction but violation of 
expectations. By varying contextual cues both within and across 
the trials of exposure, BET seeks to enhance fear tolerance and 
generalize and consolidate the effects of exposure (58). However, 
it cannot be ruled out that the mechanism of habituation may 
have contributed to the indicated results.
Exposure depends on another treatment component, the 
establishment of a sufficiently strong and stable working alliance 
(59–61). A recent study by Hammer et  al. (32) indicated that 
implementation of CER was followed by a significant reduction 
in the use of force as measured by number of resolutions. Being 
a comprehensive contextual intervention founded in a distinct 
therapeutic stance, the CER strategy may facilitate both extinc-
tion of behavioral disturbances and promote motivation for and 
willingness to engage in exposure therapy.
reconsidering “Treatment resistance”  
in the Patient group
The common treatment response across diagnostic categories, 
and the relatively better and diagnostically independent response 
among patients who presented with the lowest GAF scores at treat-
ment start, may seem counterintuitive. The results may reflect and 
underscore the transdiagnostic qualities of BET and the model’s 
capacity to reach low-functioning patients. Such findings raise the 
question of whether the term “treatment resistant” is adequate to 
describe the patient group in this study. Instead, it is possible that 
a mismatch exists between the patients’ needs and the way they 
generally are met in specialized mental health care. One obstacle 
may be found in the clinical complexity of the patient group, where 
DSM and ICD diagnoses seem to be of limited value as tools to 
guide planning and implementation of individual treatments (26, 
62, 63). The result may be what some BET patients have noted; 
throughout their long and turbulent histories in mental health 
care, they either have been given responsibility they were unable 
to handle or they have been subjected to a guardianship character-
ized by over-protective, external regulation defined as “necessary 
psychiatric care” (64–66). Failed treatment may, independent of 
what the cause has been, make health professionals start blaming 
and punishing the patient for the incompetence of the treatment 
(67, 68). An unfortunate consequence could be the too often 
frequent use of coercive measures such as forced medication, 
seclusion, and physical and mechanical restraints. The challenge 
may be to prevent and counter the development of marginalizing 
interaction patterns between patients and health-care profession-
als. By defining the problem this way, one solution is to redirect 
the focus of interventions to the context that instigates persevering 
dysfunctional behaviors on the part of the patient. By attributing 
causes of treatment resistance to the dynamics of the situations 
in which behaviors evolve, health professionals may be provided 
with tools to counteract and reverse marginalizing processes 
(32, 66).
strengths and limitations
Strengths of the study include the use of both third person and 
first person measures of patient changes, showing comparable 
improvements in symptoms across treatment. Another strength 
is the within-group associations of therapeutic components and 
processes with the outcome measures that were consistent with 
basic assumptions in BET. The major limitation of this first evalu-
ation study of BET is the naturalistic study design, with its lack of 
control group. While this limits the possibility to conclude about 
the effects of BET, the findings are still encouraging for launching 
a subsequent controlled prospective study, which we are currently 
planning. Another problem is that the apparent lack of prior 
studies related to this patient group precludes the comparison 
of our results with prior evidence. Moreover, the study included 
predominantly female patients. It is not clear whether the find-
ings can be generalized to treatment-resistant, low-functioning 
male patients.
cOnclUsiOn
Time-series data indicate that patients with severe and composite 
mental disorders who previously have appeared treatment resist-
ant may benefit from BET in a hospital setting. Most importantly, 
the apparent success of BET indicates the possibility of recovery 
for these patients by ward-integrated psychotherapeutic means, 
providing an alternative to conventional treatments. While the 
evaluation data are promising, subsequent controlled studies 
are needed to establish whether BET is an effective treatment 
approach for the target patient group.
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